Smoking is the leading preventable cause of disease, disability, and premature death. Nicotine, the main psychoactive drug in tobacco, is one of the most heavily used addictive substances, and its continued use is driven through activation of nicotinic acetylcholine receptors (nAChRs). Despite harmful consequences, it is difficult to quit smoking because of its positive effects on mood and cognition that are strong reinforcers contributing to addiction. Furthermore, a formidable challenge for the treatment of nicotine addiction is the high vulnerability to relapse after abstinence. There is no currently available smoking cessation product able to achieve a >20% smoking cessation rate after 52 wk, and there are no medications that directly target the relapse process. We report here that the 7nAChR forms a protein complex with the NMDA glutamate receptor (NMDAR) through a direct protein-protein interaction. Chronic nicotine exposure promotes 7nAChR-NMDAR complex formation. Interestingly, administration of an interfering peptide that disrupts the 7nAChR-NMDAR complex decreased extracellular signalregulated kinase (ERK) activity and blocked cue-induced reinstatement of nicotine seeking in rat models of relapse, without affecting nicotine self-administration or locomotor activity. Our results may provide a novel therapeutic target for the development of medications for preventing nicotine relapse.
7 nicotinic acetylcholine receptors (7nAChRs) and NMDA glutamate receptors (NMDARs) are both ligand-gated ion channels permeable to Ca 2+ and Na + (MacDermott et al., 1986; Gray et al., 1996) . Previous studies have demonstrated modulation of NMDARs by nAChRs, although the molecular mechanism has yet to be identified (Aramakis and Metherate, 1998; Fisher and Dani, 2000; Prendergast et al., 2001; Kenny et al., 2009) . Functional regulation of ligand-gated ion channels including the 7nAChR and NMDAR is traditionally thought to be mediated through receptor phosphorylation (Levitan, 1994; Smart, 1997; Swope et al., 1999) . However, recent studies have demonstrated that they are also regulated by intracellular proteins and cell surface receptors such as G protein-coupled receptors (GPCRs) through direct protein-protein coupling (Liu et al., 2000; Sheng, 2001; Lee et al., 2002; Kim and Sheng, 2004) . To date, functional dimerization of neurotransmitter receptors has been established between GPCRs (Lee et al., 2000; Bulenger et al., 2005; Milligan and Smith, 2007) , as well as between GPCRs and ligandgated ion channels (Liu et al., 2000; Lee et al., 2002) . Dimerization between ligand-gated ion channels has not yet been reported. In the current study, we first investigated whether 7nAChR and NMDAR form a protein complex and developed a protein peptide that is able to disrupt this complex. We then determined whether this protein complex was involved in nicotineseeking behaviors using an operant conditioningbased animal behavioral paradigm: cue-induced reinstatement (Epstein et al., 2006) .
RESULTS AND DISCUSSION
To determine the existence of an 7nAChR-NMDAR complex, we tested whether NMDAR coimmunoprecipitates with 7nAChR in rat hippocampal tissue. As depicted in Fig. 1 A (top), NR2A antibody was able to coimmunoprecipitate with 7nAChR from rat hippocampal homogenate, as recognized by a specific antibody for 7nAChR with an apparent relative molecular mass of 55,000 (M r 55K). To rule out the possibility that the observed 7nAChR-NR2A interaction was caused by the nonspecificity of 7nAChR antibody, we performed a reverse coimmunoprecipitation. As shown in Fig. 1 A (bottom) , 7nAChR antibody but not 4nAChR antibody can coimmunoprecipitate the NR2A subunit from rat hippocampal homogenate. These data suggested that 7nAChR and NMDAR may form a protein complex in the rat hippocampus. Furthermore, we measured the amount of NR2A coimmunoprecipitated by 7nAChR primary antibody versus total NR2A in the same amount of hippocampal protein used in the coimmunoprecipitation experiment. As shown in Fig. 1 (B and C) , 53 ± 0.98% of NR2A forms a complex with 7nAChR in the rat hippocampus (n = 4; P < 0.05). We also examined whether 7nAChR forms a complex with NMDAR in other brain areas. As shown in Fig. 1 D (top), 7nAChR antibody was able to coimmunoprecipitate the NR2A subunit from protein extracted from the amygdala but failed to coimmunoprecipitate the NR2A subunit from proteins extracted from the striatum, prefrontal cortex, and ventral tegmental area. The expression of the NR2A and 7nAChR subunit in all of these areas was confirmed ( Fig. 1 D, bottom) . These results further validated the specificity of all the antibodies used in our coimmunoprecipitation experiments and confirmed the existence of the NR2A-7nAChR interaction.
We then tested whether the 7nAChR-NR2A complex is involved in the actions of nicotine. We hypothesized that activation of the 7nAChR may alter 7nAChR-NR2A complex formation if 7nAChR-NR2A coupling participates in the molecular mechanisms of nicotine dependence. To investigate this possibility, we examined the ability of the NR2A antibody to coimmunoprecipitate with the 7nAChR in hippocampal primary cultures treated with 1 mM choline or 50 µM choline/NMDA. As shown in Fig. 1 E, activation of 7nAChR by choline led to a significant increase in the 7nAChR-NR2A interaction. The magnitude of this change was similar to that induced by NMDA/choline cotreatment, suggesting that the interaction was up-regulated upon 7nAChR activation. We then examined the effect of chronic nicotine exposure on 7nAChR-NR2A complex formation. Rats were pretreated with either nicotine or saline for 7 d (subdermal osmotic mini pump, 6 mg/kg nicotine/day). As shown in Fig. 1 (F and G) , coimmunoprecipitation results indicated that 7nAChR-NR2A complex formation was of NR1a and NR2A subunits and the IL2 region of 7nAChR are involved in the formation of the 7nAChR-NMDAR complex, various glutathione S-transferase (GST) fusion proteins encoding the CT of the NR1a (GSTNR1a CT : E 834 -S 938 ) and NR2A (GST-NR2A CT : D 1350 -V 1464 ) subunits or the IL2 of the 7 (GST-7 IL2 : R 316 -P 469 ) and 4 subunit of nAChR (GST-4 IL2 : V 332 -K 595 ) were prepared and used in affinity purification assays. As shown in Fig. 2 A (top), both GST-NR1a CT and GST-NR2A CT but not GST alone precipitated solubilized hippocampal 7nAChR. Similarly, GST-7 IL2 but not GST-4 IL2 or GST alone precipitated solubilized hippocampal NR2A subunits (Fig. 2 A,  bottom) . Thus, 7nAChR and NMDAR can interact with each other through the IL2 of 7nAChR and the CT of NR1a and NR2A.
Although these results demonstrate the presence of the 7nACh-NMDA protein complex in rat hippocampal tissue, they do not show whether the 7nACh-NMDAR complex significantly enhanced in the hippocampus of rats chronically exposed to nicotine compared with animals treated with saline. These data implicate the formation of 7nAChR-NR2A complexes in the actions of nicotine.
We reasoned that if enhanced 7nAChR-NR2A coupling plays a role in the pathophysiology of nicotine dependence, disruption of 7nAChR-NR2A coupling might exert anti-addiction effects. To develop a protein peptide able to disrupt 7nAChR-NR2A coupling, we performed a series of biochemical analyses to identify the regions of the 7nAChR and NR2A that are essential for 7nAChR-NR2A complex formation. Both the carboxyl tail (CT) of the NR1/NR2A subunits and the second intracellular loop (IL2) of 7nAChR contain putative consensus sequences for receptor phosphorylation and potential binding sites for various proteins important in signaling (e.g., PSD-95, calmodulin, and Src kinase; Kornau et al., 1995; Ehlers et al., 1996; Wyszynski et al., 1997; Charpantier et al., 2005) . To determine whether the CT regions dissected into two smaller fragments, 7 IL2-1-1 : R 316 -L 335 and 7 IL2-1-2 : K 326 -M 345 , with a 10-aa (K 326 -L 335 ) overlapping region to avoid the possible disruption of the binding motif (Fig. 2 E,  top) . Affinity purification assays identified 7 IL2-1-2 : K 326 -M 345 as the specific region of 7 that formed a protein complex with NR2A. As shown in Fig. 2 E (bottom) , GST-7 IL2-1-2 was able to precipitate NR2A, whereas GST-7 IL2-1-1 and GST alone failed to precipitate NR2A from solubilized rat hippocampal tissue.
Consistent with the results of the affinity purification experiments, in vitro translated [ 35 S]NR2A CT probe hybridized only with GST-7 IL2-1 (Fig. 2 F) and GST-7 IL2-1-2 (Fig. 2 G) . As GST-7 IL2-1-1 and GST-7 IL2-1-2 were designed with 10-aa (K 326 -L 335 ) overlapping regions, the fact that only GST-7 IL2-1-2 interacted with the NR2A CT suggests that the L 336 -M 345 region of IL2 of 7nAChR is critical in the direct proteinprotein interaction between 7nAChR and the NR2A subunit of NMDAR. This was further confirmed by the results of coimmunoprecipitation experiments. As shown in Fig. 2 was formed through a direct interaction or indirectly via the involvement of an accessory binding protein. Using in vitro binding assays, we provide evidence that the 7nAChR and NR2A subunits interact directly. As shown in Fig. 2 B (top) , an in vitro translated [ 35 S]7 IL2 probe hybridized with GST-NR2A CT but not GST-NR1a CT or GST alone, indicating that a direct protein-protein interaction can occur between the 7nAChR and the NR2A subunit, whereas the association between 7nAChR and NR1a subunits occurred most likely via an interaction between the NR1a and the NR2A subunits. Similarly, the [ 35 S]NR2A probe hybridized with GST-7 IL2 but not GST-4 IL2 or GST alone (Fig. 2 B, bottom) , confirming the specificity of the direct protein-protein interaction between 7nACh and NR2A subunit of NMDAR.
To confirm these results and to delineate the region of the 7 IL2 involved in the interaction with NR2A, five 7 IL2 GST fusion proteins (7 IL2-1 : R 316 -M 345 , 7 IL2-2 : K 346 -A 375 , 7 IL2-3 : G 376 -V 405 , 7 IL2-4 : V 406 -K 435 , and 7 IL2-5 : I 436 -P 469 ) were constructed (Fig. 2 C) and used in affinity purification assays. As shown in Fig. 2 D, only GST-7 IL2-1 was able to precipitate NR2A, thus defining a discrete region of the 7nAChR that interacted with NR2A. Using a similar approach, 7 IL2-1 was Furthermore, we generated an interfering protein peptide, TAT-7pep2[L 336 -M 345 ], which can disrupt the formation of this 7nACh-NMDAR complex. Most importantly, we found that administration of this interfering peptide blocked cue-induced reinstatement of seeking. Our data not only provide the first evidence for a functional interaction between different ligand-gated ion channels through heterodimerization, but also point to a novel therapeutic target with direct implications for the treatment of relapse.
MATERIALS AND METHODS
Primary dissociated cell culture. Hippocampus was collected from fetal (embryonic day 18) Wistar rats. Pregnant rats were anesthetized by inhalation of halothane or isoflurane and killed by cervical dislocation, and were fetuses removed. The dissection and dissociation were performed in ice-cold HBSS (without Ca 2+ and Mg 2+ ; Gibco) supplemented with 10 mM Hepes, pH 7.4, and 1 mM sodium pyruvate. Neurons were mechanically dispersed by trituration using glass Pasteur pipettes with reduced tips and then added to plating solution composed of 89.5% Neurobasal (Gibco), 10% horse serum, 0.5% penicillin/streptomycin (P/S). The cells were plated on glass coverslips coated with 0.1 mg/ml poly-d-lysine in borate buffer. The cell density was 50,000-80,000/ml. After 5/6 h of plating, half of the plating solution was replaced by feeding solution containing 98% Neurobasal, 2% B-27 supplement, 0.5 mM l-glutamine, and 0.5% P/S (all from Gibco). Twice per week, half of the solution was replaced with fresh feeding solution. After 6 d of plating, 5 µM Ara-C was added to stop the growth of glial cells.
GST fusion proteins.
To construct GST fusion proteins encoding fragments of NR1, NR2A, 4nAChR, and 7nAChR subunits, cDNA fragments were amplified by PCR with specific primers. Except where specified, all 5 and 3 oligonucleotides incorporated BamH1 (GGATCC) and Xho1 sites (CTCGAG), respectively, to facilitate subcloning into the pGEX-4T3 vector. GST fusion proteins were prepared from bacterial lysates as described by the manufacturer (GE Healthcare). To confirm appropriate splice fusion and the absence of PCR-generated nucleotide errors, all constructs were sequenced.
Protein affinity purification, in vitro binding, coimmunoprecipitation, and Western blot. Coimmunoprecipitation, affinity pull-down, and Western blot analyses were performed as previously described (Liu et al., 2000; Lee et al., 2002; Pei et al., 2010) . For coimmunoprecipitation experiments, solubilized rat hippocampal extracts (500700 µg protein) were incubated in the presence of specific primary antibodies anti-NR2A (EMD Millipore), anti-4 (EMD Millipore), anti-7 (Santa Cruz Biotechnology, Inc.), or 12 µg control IgG for 4 h at 4°C, followed by the addition of 20 µl protein A/G agarose (Santa Cruz Biotechnology, Inc.) for 12 h. Pellets were washed, boiled for 5 min in SDS sample buffer, and subjected to SDS-PAGE. 2050 µg of extracted protein was used as control in each experiment. For affinity purification experiments, solubilized hippocampal extracts (50-100 µg protein) were incubated with glutathione-Sepharose beads (GE Healthcare) bound to 50100 µg GST fusion proteins at room temperature for 1 h. Beads were washed, boiled for 5 min in SDS sample buffer, and subjected to SDS-PAGE. After transfer of proteins onto nitrocellulose, membranes were Western blotted with polyclonal 4 antibody (EMD Millipore), polyclonal 7 antibody (Santa Cruz Biotechnology, Inc.), -tubulin (SigmaAldrich), Phospho-Erk1/2 and Erk1/2 (Cell Signaling Technology), or monoclonal NR2A antibody (BD). For in vitro binding experiments, glutathione beads carrying 20 µg GST fusion proteins were incubated at room temperature for 1 h with [ 35 S]methionine-labeled probes. The beads were then washed six times with PBS containing 0.1-0.5% (vol/vol) Triton X-100 and eluted with 10 mM glutathione elution buffer. Eluates were separated by SDS-PAGE and visualized by autoradiography using BioMax (Kodak) film.
We have shown that the 7nACh-NR2A interaction is up-regulated in brain tissue from rats chronically exposed to nicotine, and we have generated an interfering peptide that can disrupt the 7nACh-NR2A interaction. We then investigated whether disrupting the 7nACh-NR2A interaction would affect behaviors related to nicotine dependence. The ability of transactivator of transcription (TAT)-7pep2 [L 336 -M 345 ] to disrupt 7nACh-NR2A interaction in vivo was confirmed by coimmunoprecipitation experiments. As shown in Fig. 2 I, TAT-7pep2 [L 336 -M 345 ] (intracerebroventricular [ICV] , 40 nmol) but not TAT alone significantly blocked the 7nAChR-NR2A interaction. We initially evaluated the effects of the interfering peptide on operant self-administration of nicotine. ICV injection of TAT-7pep2[L 336 -M 345 ] peptide had no effect on nicotine self-administration behaviors (not depicted). We then examined the effects of the 7pep2[L 336 -M 345 ] peptide in a reinstatement procedure that is a validated animal model of relapse. As shown in Fig. 3 (A and B) , reexposure to cues previously associated with nicotine selfadministration reinstated nicotine seeking, as indexed by increased responding on the active lever previously associated with nicotine delivery. ICV injection of 12 or 40 nmol TAT-7pep2[L 336 -M 345 ] blocked reinstatement of nicotine seeking.
To exclude the possibility that the inhibitory effect of the TAT-7pep2[L 336 -M 345 ] peptide is caused by a general suppression of behavior, we next tested whether or not TAT7pep2[L 336 -M 345 ] peptide would affect locomotor activity. TAT-7pep2[L 336 -M 345 ] peptide did not affect locomotor activity (not depicted). The absence of effects on nicotine self-administration and general locomotor activity indicated that the attenuation of cue-induced reinstatement of these various reinforcers by TAT-7pep2[L 336 -M 345 ] did not appear to be caused by an impairment of motor function. Collectively, these results showed that TAT-7pep2 had a specific effect on cue-induced nicotine reinstatement without affecting the general motor activity.
Accumulated evidence has demonstrated that extracellular signal-regulated kinase (ERK) activity is associated with drug reinstatement (Lu et al., 2005 (Lu et al., , 2006 Schroeder et al., 2008; Shiflett et al., 2008) . To examine the potential downstream signaling that is involved in 7nACh-NMDAR protein complex formation, we measured ERK1/2 activation by Western blot analysis using anti-phospho-ERK antibody after reinstatement testing. As shown in Fig. 3 (C-E) , ] peptide injection but not the TAT injection significantly reduced phospho-ERK1 and phosphor-ERK2 levels induced by a nicotine-associated cue, which also induced reinstatement. There was no significant change in the total ERK1 and ERK2 level. These data suggest that ERK signaling may be part of the downstream pathway associated with 7nACh-NMDAR protein complex formation.
In summary, our results provide the first direct evidence that two distinct ligand-gated ion channels can form a protein complex through a direct protein-protein interaction.
Using standard stereotaxic techniques, 23-gauge stainless steel guide cannulae (Plastics One) were implanted into the right lateral ventricle 1 mm over the target region and affixed to the skull by dental acrylic and jeweler screws. The final coordinates for the injector tip (from Bregma) are as follows: AP 1 mm, LM 1.4 mm, and DV 3.7 mm from the dura. ICV infusions were administered by a 10-µl syringe connected via polyethylene tubing to a 30-gauge injector that extended 1 mm below the tip of the guide cannula. At the end of the experiment, cannula patency was confirmed with an ICV injection of 50 ng angiotensin and by observing subsequent water drinking behavior. Placements were considered accurate if a rat started to drink within 1 min of the infusion and sustained drinking over 2 min. Three rats were eliminated from the analysis of the data as the result of blocked i.v. or ICV cannulae (two) or because they did not reach extinction criterion.
Locomotor testing. After recovery from surgery, rats were habituated to the locomotor activity boxes daily for 1-h sessions for 4 d. Horizontal activity was measured by the number of infrared beam breaks over this period. After the habituation period, rats were pretreated with peptide or scrambled control peptide, and effects on locomotor activity were recorded for 1 h.
Data analysis.
Data are presented as mean ± SEM. For the neurochemical data, one-way ANOVAs were used, with planned comparisons for post hoc analyses. For reinstatement experiments, total lever pressing was analyzed with mixed ANOVAs using appropriate between-and within-subject factors. Significance was set at  = 0.05.
TAT-conjugated peptides. The 7-pep1 and 7-pep2 peptides were rendered cell permanent by fusing each to the cell membrane transduction domain of the HIV-1 TAT protein (Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-ArgArg-Arg).
Implantation of osmotic mini pumps. Adult male Long-Evans rats (Charles River) weighing 250-275 g were surgically implanted with subcutaneous osmotic mini pumps (C type 2001; Alzet Osmotic Pumps) designed to deliver a continuous infusion of nicotine for 7 d according to methods described previously (Shram et al., 2008) . To implant the mini pumps, rats were anesthetized with isoflurane, and then a small incision was made between the shaved scapulae and the pump was inserted under the skin, which was then sutured. Rats in the nicotine treatment groups were implanted with pumps set to deliver nicotine at a dose of 6 mg/kg/day nicotine (in base form) for 7 d. Control rats were implanted with a sham pump.
Nicotine self-administration and reinstatement of nicotine seeking. Male Long-Evans rats underwent training for operant responding for 45-mg sucrose pellets for 3 d. They were then implanted with catheters into the right jugular vein under general anesthesia (75 mg/kg ketamine/10 mg/kg xylazine, i.p.) according to methods described previously (Corrigall and Coen, 1989; Lê et al., 2006; Shram et al., 2008) . After recovery from surgery, rats were trained to self-administer nicotine in operant chambers (Med Associates). Each chamber was equipped with two levers located 2.5 cm above the floor. Depressing the active lever activated a high speed microliter syringe pump (PHM-104; Med Associates). Pressing the inactive lever was recorded but had no programmed consequences. A white cue light was positioned above the active lever, and a tone generator (2,900 Hz) was located directly above the cue light; both visual (40 s) and auditory (1 s) stimuli were turned on when a nicotine reinforcement was obtained. A modified 22-gauge cannula was attached to the i.v. catheter on a daily basis, and this was connected to a fluid swivel with Tygon tubing protected by a metal spring. The swivel was attached to syringe containing nicotine solution with Tygon tubing.
Rats initiated self-administration of nicotine (0.03 mg/kg/infusion) under an FR-1 schedule for five daily 1-h sessions. Time out after nicotine infusion was 40 s, and during this time, pressing on the active lever had no programmed consequences but was recorded. Rats were then placed on FR-2 and FR-3 schedules for three and four sessions each, respectively. They were then implanted with ICV cannulae (as described in the next section) for subsequent injection of the peptide. Nicotine self-administration was then restabilized for 3 d at FR-3 schedule after recovery from surgery. The effects of TAT-7pep2 (TAT, TAT-7-pep2: 12 or 40 nmol in 4 µl vehicle) on nicotine self-administration were examined in 12 rats that achieved stable nicotine self-administration in a Latin square design. The peptide was infused ICV over 60 s, and the injector remained in place for an additional 60 s, 1 h before self-administration testing.
To evaluate the effects of peptide on reinstatement of nicotine seeking, a separate group of rats (n = 12) trained to self-administer nicotine was used. Extinction of their nicotine self-administration was performed until the rats pressed on the active lever <15 times during a 1-h session. Extinction sessions (14 sessions, 1 session per day) were performed in the same manner as those described for the self-administration with the exception that pressing on the lever did not deliver nicotine nor did it activate light + tone cues previously paired with nicotine delivery.
The effects of TAT-7pep2 (TAT, TAT-7-pep2: 12 or 40 nmol in 4 µl vehicle) on reinstatement of nicotine seeking induced by reexposure to the light + tone cue were examined in a Latin square design. The peptide was infused ICV over 60 s, and the injector remained in place for an additional 60 s, 1 h before reinstatement testing. For reinstatement testing, a light + tone cue without delivery of nicotine marked the beginning of the session, and for the remainder of the session the cues were delivered on an FR-3 schedule, as during self-administration. A minimum of two daily extinction sessions occurred between test days.
ICV cannulation surgery and microinjection. Surgery was performed under ketamine/xylazine anesthesia as described in the previous section.
